Tybourne Capital Management (hk) Ltd

Investment Portfolio & 13F Holdings Analysis

About

TYBOURNE CAPITAL MANAGEMENT (HK) LTD is an institutional investment manager that filed its latest Form 13F for 2025Q1, reporting 5 holdings worth $0.0 billion. Form 13F filings provide transparency into the equity holdings of institutional investment managers with over $100 million in assets under management. This page displays the most recent portfolio holdings, allowing investors to track position changes, new investments, and portfolio composition.

AI_NATIVE detailed information: This accession holds the following tickers:[
  "FBRX",
  "BCYC",
  "SLRN",
  "TSHA",
  "ZNTL"
]

Filing Details

13F-HR • 2025-03-31

SEC FilingSEC DataHachi Filing

Report Date: 2025-03-31
Filing Date: 2025-05-15
Total Holdings: 5
Total Value: 23555343
Accession Number: 0001553936-25-000007
Form Type: 13F-HR
CIK: tybourne-capital-management-hk
Manager Name: Tybourne-Capital-Management-Hk

Data Enrichment

100% identified

5 identified0 unidentified

Holdings

SEC FilingSEC DataHachi Filing

Manager:

5 positions • $23,555.343K total value

5 positions

Manager:

SEC FilingSEC DataHachi Filing

Search and click to pin securities to the top

Sort by:

ACELYRIN, Inc.

SLRN|00445A100

Shares:2.9M

Value:$7.2M

Taysha Gene Therapies, Inc.

TSHA|877619106

Shares:3.7M

Value:$5.1M

BICYCLE THERAPEUTICS PLC

BCYC|088786108

Shares:576.3K

Value:$4.9M

Forte Biosciences, Inc.

FBRX|34962G208

Shares:620.0K

Value:$4.8M

Zentalis Pharmaceuticals, Inc.

ZNTL|98943L107

Shares:961.5K

Value:$1.5M

Instrument	Shares		Other Manager	Value
ACELYRIN, Inc.(SLRNcusip00445A100)	2.9M	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$7.2M	QoQ -21.33% (-$1.9M) YoY -63.40% (-$12.4M)
Taysha Gene Therapies, Inc.(TSHAcusip877619106)	3.7M	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$5.1M	QoQ -19.65% (-$1.3M) YoY -51.56% (-$5.5M)
BICYCLE THERAPEUTICS PLC(BCYCcusip088786108)	576.3K	QoQ -54.60% (-693.2K) YoY -62.69% (-968.7K)	All Managers (Combined)	$4.9M	QoQ -72.46% (-$12.9M) YoY -87.28% (-$33.6M)
Forte Biosciences, Inc.(FBRXcusip34962G208)	620.0K	QoQ 0.00% (-0) YoY NEW(+620.0K)	All Managers (Combined)	$4.8M	QoQ -65.83% (-$9.3M) YoY NEW(+$4.8M)
Zentalis Pharmaceuticals, Inc.(ZNTLcusip98943L107)	961.5K	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$1.5M	QoQ -47.52% (-$1.4M) YoY -89.91% (-$13.6M)